• Malaria Vaccine
• Hookworm Vaccine
• Schistosome Vaccine
• Genomic tools for Malaria
• Interactive maps and epidemiology
• Immune Evasion
• Allergy and Ascariasis
• Mosquito control
• Immunocompromised
  Hosts
• Anti-malarial drug development
• Anti-parasitic drug development
• Conflict and parasites
• Parasites of Bees
• Morgellons:
  Fact or Fiction?
• Eradication of
  Chaga’s Disease
• The world’s most successful parasite
• Guinea worm eradication

References

1. Wilson RA, Coulson PS. Why don’t we have a schistosomiasis vaccine? Parasit. Today. 1998 Mar;14(3):97-99.

2. Ross AG, Bartley PB, Sleigh AC, Olds GR, Williams GM, McManus DP. Review: Schistosomiasis. N Engl J Med. 2002. April;346(16):1212-1220.

3. Haseeb MA, Eveland LK. Schistosoma mansoni: a chemoattractive factor release by males and its receptor on females. Experentia. 1991. Jun;47:970-974

4. Bergquist NR. Schistosomiasis Vaccine Development: Progress and Prospects. Mem Inst Oswaldo Cruz. 1998. May; 93(1):95-101.

5. Ogilvie BM, Smithers SR, Terry RJ. Reagin-like antibodies in experimental infections of Schistosoma mansoni and the passive transfer of resistance. Nature. 1966 Mar 19;209(5029):1221-3

6. Coulson PS, Wilson RA. Recruitment of lymphocytes to the lung through vaccination nhances the immunity of mice exposed to irradiated schistosomes. Infect Immun. 1997. 65: 42-48.

7. Pearce EJ, James SL, Hieny S, Lanar DE, Sher A. Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen. Proc Natl Acad Sci USA. 1988. 85:5678-5682.

8. Soisson LM, Masterson CP, Tom TD, McNally MT, Lowell GH, Strand M. Induction of protective immunity in mice using a 62-kDa recombinant fragment of a Schistosoma mansoni surface antigen. J Immuno. 1992. 149:3612-3620.

9. Moser D, Tendler M, Griffiths G, Klinkert M. A 14kD Schistosoma mansoni polypeptide is homologue to a gene family of fatty acid binding proteins. J Biol Chem. 1991;266:8447-8454.

10. Shoemaker C, Gross A, Gebremichael A, Harn D. cDNA cloning and functional expression of the Schistosoma mansoni protective antigen triose-phosphate isomerase. Proc Natl Acad Sci. 1992. 89: 1842-1846.

11. Koster B, Hall MRT, Strand M. Schistosoma mansoni: immunoreactivity of human sera with the surface antigen Sm23. Exp Parasitol. 1993. 47:970-974.

12. Taylor MG. Production and testing of Schistosomosa japonicum candidate vaccine antigens in the natural ovine host. Vaccine. 1998. 12;319-326.

13. Zhang DM, Pan WQ, Qian L, Duke M, Shen LH, McManus DP. Investigation of recombinant Schistosoma japonicum paramyosin fragments for immunogenicity and vaccine efficacy in mice. Parasite Immunol. 2006 Mar;28(3):77-84.†

14. Levy S. Shoman T. The Tetraspanin wed modulates immune-signalling complexes. Nat. Rev. Immunol. 5, 136-148 (2005).

15. Jones MK, Gobert GN, Zhang L, Sunderland P, McManus DP. The cytoskeleton and motor proteins of human schistosomes and their roles in surface maintenance and host-parasite interactions. Bioessays. 2004 Jul;26(7):752-65.

16. Zhu Y, Si J, Harn D.A, Xu M, Ren J, Yu, C, Liang Y, Yin X, He W, Cao G. Schistosoma japonicum triose-phosphate isomerase plasmid Dna vaccine protects pigs against challenge infection. Parasit. 2006. Jun;132(11): 1-5.

17. Tran MH, Pearson MS, Bethony, JM, Smyth DJ, Jones MK, Duke M, Don TA, McManus DP, Correa-Oliveira R, Loukas A. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against Schistosomiasis. Nat. Med. 2006. Jul:12(7):835-840.

18. Liu JM, Wang AH, Chen YJ, Gu HM. Studies on the anti-genicity and protein pattern of soluble antigens from a germinal cell line of echinococcus granulosus. J Agric Biotech. 1998;6:277-280.

19. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, Pompa J, Villalovis RM, Paz M. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine. 2003 Jun 20;21(21-22):2882-9.

20. World Health Organization. Options for a Global Fund for New Vaccines. Geneva Convention: World Health Organization, 1999. www.who.int/vaccinesdocuments/DocsPDF99/www9921.pdf

21. Training in Tropical Diseases (TDR). Important progress in schistosomiasis vaccine development. TDR News Publications. No. 63 October 2000.

22. James SL, Colley DG, 2001. Progress in accine development. Mahmoud AAF, ed. Schistosomiasis. London: Imperial College Press, 469-495.

23. Todd CW, Colley DG, 2002. Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni. Am. J. Trop Med. Hyg, 66 (4), 348-558.

24. World Health Organization. Schistosomiasis. Division of Parasitic Diseases. Updated April, 2007. http://www.who.int/vaccine_research/diseases/soa_parasitic/en/index5.html

25. Hillyer GV, Tsang VC, Vivas-Gonzalez BE, 1999. Age-specific decrease in seroprevalence of schistosomiasis in Puerto Rico. Am J Trop Med Hyg 60: 313–318.

26. Mc Manus, DP. The search for a vaccine against schistosomiasis – a difficult path but an achievable goal. Immunological Reviwes 1999. Vol. 171: 149-161.

27. Capron A, Capron M, Dombrowicz D, Riveau G. Vaccine strategies against schistosomiasis: from concepts to clinical Trials. Int Arch Allergy Immunology 2001; 124: 9-15.

28. Harn, Donald. Harvard School of Public Health. Telephone Interview. May 7 2007.

29. Afzal. Siddiqui. Texas Tech Medical Center. Email Interview. May 17 2007.

30. Lewis, Fred. Biomedical Research Institute. Email Interview. May 17 2007.

31. LoVerde, Phillip. Southwest Foundation for Biomedical Research. Email Interview. May 18 2007.